In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals (INO – Research Report). The company's shares closed last Friday at $1.99, close to its 52-week low of $1.60. According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of -43.0% and a 10.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Aquestive Therapeutics, and Oramed Pharmaceuticals. Currently, the analyst consensus on Inovio Pharmaceuticals is a Hold with an average price target of $3.00, which is a 63.0% upside from current levels.
https://www.tipranks.com/news/blurbs/inovio-pharmaceuticals-ino-gets-a-hold-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Inovio Pharmaceuticals Charts.
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Inovio Pharmaceuticals Charts.